StanisicS.; BertolottoA.; BertoP.; Di ProcoloP.; MorawskiJ. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. Global & Regional Health Technology Assessment, v. 6, n. 1, 10 abr. 2019.